Alzheimer's disease (AD) is a disorder characterised by a progressive deterioration in memory and other cognitive functions. Neurofibrillary tangles (NFT) are a major pathological hallmark of AD, these are aggregations of paired helical filaments (PHF) comprised of the hyperphosphorylated microtubule associated protein tau. Several kinases, such as glycogen synthase kinase 3 beta (GSK3␤) and c-Jun N-terminal kinase (JNK), phosphorylate tau at sites that are phosphorylated in PHF. Dishevelled 1 (DVL1) is thought to act as a positive regulator of the wnt signalling pathway, and inhibits GSK3␤ activity preventing ␤-catenin degradation and thus allowing wnt target gene expression. JNK activation is also regulated by DVL1, however it is unclear if this is via the wnt signalling pathway. These observations suggest a central role for DVL1 in tau phosphorylation and AD and led us to investigate DVL1 as a candidate gene for this disorder. We determined the genomic structure of the DVL1 gene by sequencing and data mining and searched for sequence variations in the coding sequences and flanking introns. The DVL1 gene spans a region of approximately 13.8 kb (not including the 5Ј untranslated region) and is encoded by 15 exons. Analysis of over 4.3 kb of sequence, including 98% of exonic sequences and introns 2, 3, 6, 7, 9, 10, 11 and 12, revealed there to be six rare (Յ6%) sequence variations. None of these had any association with late onset AD. This would suggest that polymorphic variations in the coding sequences of DVL1 are not important in AD. However further analysis of regulatory regions may lead to the identification of other sequence variations which may be implicated in AD.
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AD is characterised by two major neuropathological features, neuritic plaques and neurofibrillary tangles (NFT). NFT are intraneuronal inclusions of paired helical filaments (PHF), mostly comprised of highly phosphorylated microtubule associated protein tau. Tau promotes microtubule (MT) assemble in vitro 2 and stabilises MT in vivo 3 and it is thought that phosphorylation inhibits these processes and leads to PHF formation. Several mitogen activated protein (MAP) kinases, such as c-Jun N-terminal kinase (JNK), and glycogen synthase kinase 3 beta (GSK3␤) have been shown to phosphorylate tau in vitro, in cell at sites that are phosphorylated in PHF. [4] [5] [6] [7] JNK and GSK3␤ are regulated by the dishevelled 1 gene (DVL1), the latter as part of the wnt signalling pathways. [8] [9] [10] [11] Activation of the wnt signalling pathway is thought to cause DVL1 to inactivate GSK3␤ through complex-formation with adenomatous poliposis coli (APC), axin and ␤-catenin proteins, 8 whereas JNK is activated by DVL1. 10, 11 The mechanism by which this JNK activation occurs is unclear, however, it has been demonstrated that a DEP (dishevelled, egl-10 and pleckstrin) protein binding domain found at the C-terminal of DVL1 is essential for JNK activation. 10 It has been suggested that the wnt signalling pathway is altered in AD, 8, 9 therefore DVL1 is a very strong candidate gene for AD. Furthermore a recent genome scan has shown suggestive linkage (LOD score 1.33, markers D1S548 and D1S1592) to the distal end of chromosome 1 p to AD, where DVL1 is located.
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DVL1 is a cytoplasmic phosphoprotein 13 encoding a 670-amino acid polypeptide mapping to chromosome 1p36. 14 In Drosophila it regulates cell proliferation, acting as a transducer molecule for developmental processes, including segmentation and neuroblast specification.
14 DVL1 is part of a multi-gene family of proteins that contain three highly conserved species of protein binding domains: an N-terminal DIX (dishevelled and axin) domain; a central PDZ (PSD-95, discs-large and ZO-1) domain; and a DEP domain. DVL1 is highly expressed in both adult and fetal tissues such as skeletal muscle and pancreas but is also found in the brain and neural tube.
14 In contrast to JNK activation, all three protein binding domains are required for GSK3␤ inactivation and thus ␤-catenin upregulation. 10, 15 A chromosomal deletion that includes the DVL1 gene causes severe morphological abnormalities in children. 16 However knockout mice lacking DVL1 are viable, fertile, and structurally normal but show abnormal social behaviour and several neurological defects. 17 Recent studies demonstrated that overexpression of mouse DVL1 causes inhibition of GSK3␤ mediated tau phosphorylation. 18 Furthermore Strovel et al 19 demonstrated the inability of producing stable cell lines overexpressing DVL1. They showed that DVL1 causes cell death due to the induction of apoptosis in an APC-dependent manner. This led us to hypothesise that a subtle variation in the coding or regulatory region of DVL1 may have an influence later in life and in AD. We therefore sought to sequence the DVL1 gene including some of its introns in a series of AD cases and controls to identify polymorphisms and then investigate these in AD.
We systematically sequenced 1979 bp of the DVL1 coding sequence and 2337 bp of the non-coding sequence in 24 control and 24 AD samples to identify differences between the two populations. Sequencing and BLAST 20 analysis of the cDNA (Acc. No. AF006011) sequence against the NCBI (National Centre for Biotechnology Information) htgs (unfinished high throughput genomic sequences) nucleotide database, led us to determine the genomic structure of the DVL1 gene (see Figure 1 and Table 1 ). DVL1 is encoded by 15 exons similar to that of the mouse DVL1 gene 21 ranging in size from 68 bp (exon 10) to 374 bp (exon 15) spanning a region of approximately 13.8 kb (not including the 5Ј untranslated region) with the largest and smallest introns being 6139 bp (intron 1) and 69 bp (intron 7) respectively. We fully sequenced exons 2-14 and partially sequenced exons 1 and 15. Due to sequencing primer design constraints, the first 21 bp of exon 1 and the last 12 bp of exon 15 were not sequenced. We also fully sequenced introns 2, 3, 6, 7, 9, 10, 11, 12 and partially sequenced other introns. The other introns and the 5Ј and 3Ј untranslated region were not sequenced due to time constraint. The coding sequence we elucidated is identical to the Semenov sequence (Acc.No. AAB65242). The DIX domain is located in exons 1-3, the PDZ domain is in exons 7-10 and the DEP domain is encoded by exons 12 and 13.
Sequencing analysis detected six single nucleotide polymorphisms (SNPs). We identified a rare silent coding SNP in exon 1 at codon 22 position nt 69 C/T (relative to Acc.No. AF006011) with rare allele frequency of 1%. Furthermore we identified five rare noncoding SNPs at positions nt 98876 G/A (intron 2), nt 99188 C/A (intron 3), nt 99890 G/A (intron 5), nt 101121 A/T (intron 6) and 102296 C/T (intron 11) with rare allele frequencies of Յ6% (relative to Acc. No. AL139287.6) (see Table 2 ). Table 1 shows the sizes of exons and introns.
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We examined each SNP in larger sample populations of ADs and controls to determine whether these alterations were potential disease-related or non-pathogenic. Statistical analysis showed that all of the polymorphisms examined are in Hardy-Weinberg equilibrium. Haplotype analysis showed that SNPs 98876 G/A and 102296 C/T were in strong linkage disequilibrium (DЈ = 1.00, df = 3, P Ͻ 10
−7
). When comparing ADs to controls no statistically significant association of any SNP was found for individual alleles (see Table 3 ) and genotypes (data not shown).
As the APOE ⑀4 allele has repeatedly been associated with risk for AD, this association should be seen in our Caucasian AD case-control sample. Indeed, statistical analysis of the sample showed there to be a highly significant association between APOE ⑀4 allele frequency and AD (0.36) vs controls (0.16) (P = 0.001; OR = 3.02, CI 1.44-6.40). 22, 23 As all SNPs were found to be rare (Յ6%), we did not perform any further statistical analysis of the sample, such as stratification by APOE ⑀4 status, sex, age of onset and 'probable' or 'possible' AD.
To ensure that our analyses were specific to DVL1 we performed radiation hybrid mapping 24 (data not shown) using several primer pairs. This revealed linkage of our PCR fragments to chromosome 1p36 with LOD scores greater than 7, therefore confirming the specificity of our investigation. No other chromosomal location showed any significant linkage.
In this study we have elucidated the genomic organisation of the human DVL1 gene and have investigated the frequency of polymorphisms in the DVL1 gene and analysed their possible involvement in AD. Statistical analysis showed there to be no significant association between any of the detected polymorphisms and AD. However, control populations are an intrinsic problem in AD genetic studies and this is as true for the control group we used as for those used in other studies. We included only controls with no evidence of cognitive impairment (MMSE Ͼ 25) but it remains possible that we included a few individuals in the early, perhaps presymptomatic, stages of dementia. However it is unlikely that this would have affected our results. As we have investigated effectively 96 chromosomes for the DVL1 gene, we are confident that we have detected all common SNPs present in regions examined in the Caucasian population. The power in this study for detecting SNPs with frequencies of 10% is Ͼ95% and for detecting SNPs with frequencies of 5% is slightly less at ෂ90%, based on the number of chromosomes examined. Future analysis may reveal further SNPs in the promoter, intron 1 and other introns. The number of SNPs detected in non-coding regions examined was one SNP per 511 bp, corresponding to a nucleotide diversity of = 0.000453 ± 0.00011. We also detected one synonymous SNP per 1979 bp coding region screened, corresponding to a nucleotide diversity of = 0.000105 ± 0.000022. Although these values are lower than average nucleotide diversities previously described, [25] [26] [27] they are consistent with the nucleotide diversity values for some of the genes investigated in these studies. 25, 27 The pathological changes seen in AD, such as JNK and GSK3␤ mediated phosphorylation of tau and the disruption of ␤-catenin turnover, which are probably very relevant to the pathogenesis of AD, are not due to Molecular Psychiatry polymorphic variation we have detected in the DVL1 gene. The possible disruption of the wnt signalling pathway seen in AD could be due to polymorphism in other genes in this signalling pathway. We have recently shown that polymorphic variations in the GSK3␤ gene and its promoter are also not associated with AD.
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Methods
Subjects
All subjects used were Caucasians. The test samples consisted of: 52 community-based late onset AD cases over the age of 60 years (mean age of onset 76 (SD = 7.2)) who fulfilled the NINCDS-ADRDA criteria 28 for 'probable' (70%) and 'possible' (30%) AD, recruited from the Camberwell Dementia Case Register; 22 49 community dwelling controls aged over 75 years (mean age 80.1 (SD = 3.8)) who scored 25 points or above on 
PCR and sequencing analysis
We amplified approximately a total of 4.3 kb of DVL1 genomic sequence from lymphocyte-derived genomic DNA. Primers (MWG-Biotech, Milton Keynes, UK) used are described in Table 2 . PCR reactions were performed in a final volume of 40 l containing 50 ng DNA, 0.3 M each primer and 1 U Taq DNA polymerase (Hybaid, UK). The PCR conditions consisted of 35 cycles of 45 s at 94°C, 45 s at 50-60°C and 45 s at 72°C, preceded by 5 min at 95°C and followed by 10 min at 72°C. Products for sequencing were then purified using the Hybaid DNA purification Kit II (Hybaid, Ashford, UK). Twenty-four controls and 24 'probable' AD samples were sequenced for each of the 15 exons and introns 2, 3, 6, 7, 9, 10, 11, and 12. PCR products were sequenced in both directions using the Big Dye Terminator sequencing kit (Applied Biosystems, Warrington, UK) and relevant PCR primers. Sequencing was performed on an ABI377 automated sequencer. The sequence data were reanalysed by the Phred program, 29, 30 assembled by the Phrap program, possible polymorphic bases identified by the PolyPhred program 31 and traces viewed using the program Consed. 32 Possible SNPs detected by sequencing were further investigated by restriction fragment length polymorphism (RFLP) or single stranded conformational polymorphism (SSCP) analysis in larger cohorts of AD and control samples. SSCP analysis used 12% non-denaturing PAGE at a constant 10 V cm −1 for 14 h at 4°C. Prior to loading, samples were mixed 1:1 with formamide loading buffer and denatured at 95°C for 10 min and chilled on ice. Details of individual RFLP analyses are shown in Table 3 .
Statistics
Linkage disequilibrium was calculated using the EH program. 33 Values of DЈ, the normalised linkage disequilibrium statistic were calculated using published methods. 34 DЈ values are between 0 and 1 with larger values suggesting stronger linkage disequilibrium. Statcalc 35 was used for power calculations and for the comparison allelic distribution of SNPs between controls and ADs. Nucleotide diversity () was calculated as described by Halushka et al. 
